SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (1121)5/18/2000 11:24:00 PM
From: Jim Oravetz  Read Replies (1) | Respond to of 52153
 
FUND VIEW-Biotech valuations to triple over three years

By Nick Edwards

HONG KONG, May 18 (Reuters) - Nasdaq-listed biotechnology shares could see valuations triple over the next three years as U.S. federal drug approvals and the coveted patents that go with them begin to be awarded, a senior fund manager said on Thursday. snip....

biz.yahoo.com

No specific companies mentioned, but some general stat's on drugs in development.
Jim